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Introduction
Cervical cancer is the second most common cancer in 
women worldwide for incidence and mortality [1] and 
also the leading cancer in developing countries where 
more than 80% of the cases and related deaths occur [2]. 
In Italy, about 3,500 new cases and 1,500 deaths are re-
ported every year [3].
Different Human Papillomavirus (HPV) strains fre-
quently infect the genital tract and both epidemiological 
and experimental evidence show that some carcinogenic 
strains are associated with cervical cancer [4, 5]. Genital 
HPV types have been subdivided into high-risk, prob-
able high-risk and low- risk genotypes according to their 
association with invasive cervical cancer [5, 6]. Types 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 
82 should be considered carcinogenic or high-risk (HR-
HPV) whereas types 26, 53, and 66 should be consid-
ered probable high-risk (PHR-HPV) [5]. Among high-
risk genotypes, HPV-16 is associated with about 60% of 
the cases of cervical cancer, HPV-18 with 10%, HPV-31 
and HPV-45 with 4% each, whereas genotypes HPV-33, 
HPV-52 and HPV-58 altogether contribute to another 
2% of cervical cancer cases [7-9]. The low-risk (LR) 
HPV genotypes HPV-6 and HPV-11 are responsible for 
about 90% of genital warts [10]. 
In Puglia, an Italian region with a population of about 
four million inhabitants, cervical cancer is the second 
most common cancer (after breast cancer) in women 
and about 200 new cases are hospitalized every year 
(source: Regional Epidemiological Office). Incidence 
rate of cervical cancer is not available since a regional 
cancer registry does not exist. Very recently, a cervical 
cancer-screening program has been set up in the Re-
gion for women between 25-64 years of age based on 
clinical examination and Pap test. The women should be 
screened at intervals of three years but, at the present, 
very little data are available on the screening activity, on 
the frequency of HPV infection and the circulation of the 
different genotypes within the population.
To date, two types of prophylactic vaccines based on 
virus-like particles containing L1 capsid protein of HPV 
have been developed: a bivalent against types 16 and 
18 and a quadrivalent one against types 16, 18, 6 and 
11 [11, 12]. 
In the Puglia region, starting from 2009, the bivalent pro-
phylactic vaccine is currently used to vaccinate 12 year-
old females (starting from birth cohort of year 1997). 
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Summary
Introduction. In the Puglia region (South Italy) about 200 new 
hospitalizations for cervical cancer are registered every year. 
The study investigated the frequency of Human Papillomavirus 
(HPV) infection and the genotype distribution of HPV in a sample 
of women with known cytology attending the outpatient clinics of 
four Gynecological Departments of the University of Bari over a 
four-year period (2005-2008). 
Methods. Cervical samples from 1,168 women were analyzed for 
the presence of HPV-DNA through Polymerase Chain Reaction 
(PCR) in L1 region and reverse hybridization. The cytological 
results were associated with HPV positivity and type-specific 
prevalence. 
Results. Overall, HPV infection was found in 355 (30.4%) women. 
HPV-DNA was found in 34.4% of women with a cytological 
diagnosis of ASCUS, in 46.8% of women with Low-grade Squa-
mous Intraepithelial Lesion (LSIL) and in 87.0% of women with 
High-grade Squamous Intraepithelial Lesion (HSIL)/carcinoma. 
Also 16.0% of women with normal Pap smear were found to be 
HPV-DNA positive. The most common HPV genotype was type 16 
found in 27.3% of positives, followed by type 53 (11.5%), type 66 
(9.2%) and type 31 (9.0%). HPV genotype 18 was found in 6.4% 
of positives. Types 16 or 18 were detected in about 34% (120/355) 
of all infected women, in about 33% of LSIL and in 60% of HSIL/
carcinoma HPV-positive women. Among low risk (LR) genotypes, 
type 61 was found in 10.7% of HPV positive women, type 62 in 
8.4%, type 42 in 8.1% and type CP6108 in 7.8%. 
Discussion and conclusions. The findings of the study give evi-
dence that HPV infection is frequent in the studied cohort of 
women. The most widespread genotypes found were 16 and 53. 
These data may represent a benchmark for future evaluation after 
the recent introduction of vaccination against HPV in 12-year-old 
girls.
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Appropriate and effective preventive strategies need 
specific epidemiological information and, therefore, it is 
crucial to know the burden of HPV infection in different 
geographical areas and the genotypes circulation among 
local populations also in the view of the evaluation of 
the impact of vaccination campaigns. 
The aim of the present study was to assess the frequency 
of HPV infection and the genotype distribution of HPV 
in relation to cytological outcomes, in a sample of wom-
en attending the referral outpatient clinics of four Gyne-
cological Departments of the University of Bari (Puglia 
capital city), prior to the start of HPV vaccination pro-
gramme.
Methods
Study population
We studied 1,168 women referred for HPV testing to the 
Molecular Biology Laboratory of the Hygiene Section 
of the Department of Biomedical Sciences and Human 
Oncology of the University Hospital of Bari in the years 
2005-2008. The women attended the outpatient clinics 
of four referral Gynecological Departments of the Uni-
versity of Bari either for routine gynecologic care or for 
Pap test screening. Patients who needed a second level 
examination following a previous abnormal Pap smear 
were also enrolled. In all cases HPV-DNA detection was 
part of the diagnostic algorithm. Only women that gave 
informed consent to the study and that could provide a 
copy of written Pap test soon after receiving the result 
were enrolled in the study.
Cytological evaluation was performed by experienced 
cytopathologists of reference cytological Services of 
Departments of Pathological Anatomy of the University 
of Bari. The cytological Services that perform Pap tests 
undergo the external quality assurance activities that are 
part of the regional cancer-screening programme.
The cytological results had been reported according to 
Bethesda system. The classification was ASCUS for 
atypical squamous cell of undetermined significance, 
Low-grade Squamous Intraepithelial Lesion (LSIL), 
High-grade Squamous Intraepithelial Lesion (HSIL). 
Experimental research had been performed with the ap-
proval of the ethic committee of the University of Bari 
and was compliant with Declaration of Helsinki princi-
ples.
Sample processing and DNA extraction 
Cervical samples, taken by cotton swab or cytobrush, 
were suspended in a 20 ml preservation solution (Liqui-
prep); 1-2 ml was pelleted at 600g for 10 minutes. The 
pellets were frozen at -80°C until the test was carried 
out. For DNA extraction, the pellets were thawed and 
resuspended in 200µL of PBS solution (phosphate-buff-
ered saline). The DNA extraction was carried out start-
ing from 200 µL of volume by the use of a commercial 
kit (High Pure Viral Nucleic Acid and MagNA Pure LC 
DNA Isolation kit I, Roche Diagnostics, Milan, Italy). 
The automatic DNA extraction with MagNA Pure was 
carried out as previously described [13]. The DNA was 
eluted in a final volume of 100 µL and stored at -20°C. 
HPV typing Linear array HPV genotyping
The Linear Array HPV genotyping test (Roche Diagnos-
tics, Milan, Italy) employs the PGMY primers capable 
of amplifying a DNA fragment of approximately 450 
bp in the L1 region. An additional primer pair targets a 
fragment (268 bp) of the β-globin gene and provides a 
control for cell adequacy, extraction and amplification. 
PCR amplification, hybridization reaction and detection 
were performed according to the manufacturer’s in-
structions. The provided HPV-positive (HPV genotype 
16) and -negative controls were used. The Linear Ar-
ray HPV genotyping system can identify the following 
HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 
51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 
70, 71, 72, 73, 81, 82, 83, 84, IS39, CP6108. The strips 
were manually interpreted using the manufacturer’s ref-
erence guide, by reading the individual types down the 
length of the strip. The kit is CE marked and proved to 
be highly comparable, useful and accurate for epidemio-
logic purposes [14].
Statistical analyses
Confidence intervals at 95% (95% CI) were calculated 
by the modified Wald method. The χ2-test was used to 
compare categorical variables. A p-value < 0.05 was 
considered statistically significant. The χ2-test for linear 
trend was used to evaluate differences in the prevalence 
of HPV infection in different age groups.
Results
A total of 1,168 women were enrolled in the study popu-
lation. The mean age of the 1,141 women with known 
age was 37 years (S.D. ± 8.57, range 17-73). 
Table I shows the percentage of HPV-positives by age 
group and cytological results. Overall, HPV-DNA was 
detected in 30.4% (n = 355, 95% CI: 27.8-33.1). The 
age-specific prevalence of HPV infection was highest 
among women ≤ 24 years old (55.8%; 95% CI: 46.2-
65.0) and decreased with age, until 45-54 years old (χ2 
for trend = 17.25, P < 0.0001). Another peak of 43.7% 
(95% CI: 28.1-60.7) was observed in women ≥ 55 years 
old.
The highest rate of HPV infection was found in the 
age group ≤ 24 both in women with abnormal (64.5%, 
95% CI: 52.0-75.3) and with normal cytological results 
(42.8%, 95% CI: 29.1-57.8) while the lowest rate was 
found in the age group 45-54 years old (37.7% and 5.2% 
respectively).
Of the 524 women with an abnormal PAP test (≥ AS-
CUS), 48.1% (95% CI: 43.8-52.4) were HPV-positive 
compared to 16.0% (95% CI: 13.4-19.0) of the 644 
women with normal cytology. 
Table II shows the prevalence of HPV infection in 
women according to cytological findings. To simplify 
the analysis, nine women with a diagnosis of carcinoma 
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were included in the HSIL group. The HPV prevalence 
increased with the severity of cervical smear abnormal-
ity in all age groups. 
HPV-DNA was found in 34.4% (95% CI: 25.5-44.5) 
of women with a cytological diagnosis of ASCUS, in 
46.8% (95% CI: 41.8-51.7) of women with LSIL and in 
87.0% of women with HSIL/carcinoma (95% CI: 74.0-
94.3). 
HR-PHR HPV genotypes, alone or in association with 
other HR-PHR genotypes or LR genotypes, were found 
in 72.9% (259 out of 355) of infected women. 
The 40.6% (144 out of 355) of the HPV positive women 
had only one HR-PHR genotype and 18.6% (66) had on-
ly one LR genotype. Multiple genotypes infections were 
found in 40.8% (145) of HPV-positive women. 
The association of cytological diagnosis with HPV oc-
currence (HR-PHR or LR) and multiple or single in-
fection in HPV-positives is described in table III. The 
prevalence of HR-PHR genotypes (alone or in associa-
tion with other HR-PHR or LR genotypes) increased 
with the grade of the cytological results. HR-PHR 
types were found in 78.1% of women with ASCUS, 
in 78.8% of LSIL and in 87.5% of women with HSIL/
carcinoma. In addition, the 55.3% of women with nor-
mal Pap test but HPV-positive showed HR-PHR geno-
types. Multiple infections were detected in 37.5% of 
Tab. I. Frequency of hpv by age group in women with normal and abnormal cytology.
Cytological finding   
Normal Abnormal ( ≥ ASCUS) Total (1,168)
Age groups (years) No. HPV+ (%) 95% CIa No. HPV+ (%) 95% CIa No. HPV+ (%) 95% CIa
 ≤ 24 42 18 (42.8) 29.1-57.8 62 40 (64.5) 52.0-75.3 104 58 (55.8) 46.2-65.0
25-34 233 40 (17.2) 12.8-22.6 169 84 (49.7) 42.3-57.2 402 124 (30.8) 26.5-35.5
35-44 271 38 (14.0) 10.4-18.7 178 81 (45.5) 38.4-52.9 449 119 (26.5) 22.6-30.7
45-54 77 4 (5.2) 1.6-13.0 77 29 (37.7) 27.6-48.4 154 33 (21.4) 15.6-28.6
 ≥ 55 5 1 (20.0) 2.0-64.0 27 13 (48.1) 30.7-66.0 32 14 (43.7) 28.1-60.7
Unknown 16 2 (12.5) 2.2-37.3 11 5 (45.4) 21.2-72.0 27 7 (25.9) 11.9-45.0
total 644 103 (16.0) 13.4-19.0 524 252 (48.1) 43.8-52.4 1168 355 (30.4) 27.8-33.1
a 95% confidence intervals
chi-square test for linear trend (normal cytology) = 19.69, P < 0.0001
chi-square test for linear trend (≥ aScUS) = 11.80, P < 0.005
chi-square test for linear trend (total) = 17.25, P < 0.0001
Tab. II. Frequency of hpv infection according to pap test result and age group.
ASCUS LSIL HSILa
Age group (years) No. HPV+ (%) 95% CIb No. HPV+ (%) 95% CIb No. HPV+ (%) 95% CIb
 ≤ 24 4 2 (50.0) 15.0-85.0 53 34 (64.2) 50.7-75.7 5 4 (80.0) 36.0-97.9
25-34 20 6 (30.0) 14.3-52.1 138 68 (49.3) 41.0-57.5 11 10 (90.9) 60.1-100.0
35-44 33 11 (33.3) 19.7-50.4 132 58 (43.9) 35.7-52.4 13 12 (92.3) 64.6-100.0
45-54 24 7 (29.2) 14.7-49.4 45 15 (33.3) 21.3-48.0 8 7 (87.5) 50.8-100.0
 ≥ 55 11 5 (45.5) 21.2-72.0 7 1 (14.3) 0.5-53.3 9 7 (77.8) 44.3-94.7
Unknown 1 1 (100) - 10 4 (40) 16.6-68.8 0 0 -
total 93 32 (34.4) 25.5-44.5 385 180 (46.8) 41.8-51.7 46 40 (87.0) 74.0-94.3
aincluding 9 women with diagnosis of carcinoma
b 95% confidence intervals
Tab. III. hpv types and prevalence of multiple infections in hpv-positive women.
Squamous Intraepithelial lesions      Total (N=355)
YES (N = 252)  NO (N = 103)
ASCUS (N=32) LSIL (N=180) HSIL (N=40a)
hpv no. % no. % no. % no. % no. %
hr-phr 25 78.1 142 78.8 35 87.5 57 55.3 259 72.9
lr 7 21.8 38 21.1 5 12.5 28 27.1 78 21.9
multiple infections 12 37.5 86 47,7 12 30.0 35 33.9 145 40.8
aincluding 9 women with diagnosis of carcinoma
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women with a diagnosis of ASCUS, in 47.7% of wom-
en with a diagnosis of LSIL and in 30.0% of women 
with a diagnosis of HSIL/carcinoma. The rate of LR 
genotypes ranged from 12.5% of HSIL/carcinoma to 
21.8%of ASCUS. 
The frequency of any single HPV genotype among HPV-
positive women by cytological diagnosis is shown in Ta-
ble IV. Overall, 33 different HPV types were identified. 
Among HR-PHR, the most common HPV genotype was 
type 16 found in 27.3% of positives followed by type 
53 (11.5%), type 66 (9.3%) and type 31 (9.0%). HPV 
genotype 18 was found in 6.4%. Types 16 or 18 were 
detected in 33.7% (120/355) of infected women.
HPV type16 was detected in 21.3% of infected women 
with normal Pap test. The rate of HPV-16 infection in-
creased from 27.7% of LSIL to 45.0% of HSIL/car-
cinoma. The genotype 53, the second most frequent 
HR-PHR genotype, was found in 12.6% of women 
Tab. IV. hpv type frequency in hpv-positive women by cytological diagnoses.
Normal benign 
(103)
ASCUS (32) LSIL (180) HSIL (40)a Total (355)
 no. % no. % no. % no. % no. %
HR/PHR-HPVb
16 22 21.3 7 21.8 50 27.7 18 45.0 97 27.3
18 4 3.8 3 9.3 10 5.5 6 15.0 23 6.4
26 - - - - - - - - - -
31 8 7.7 7 21.7 17 9.4 - - 32 9.0
33 1 0.9 2 6.2 6 3.3 1 2.5 10 2.8
35 1 0.9 3 9.3 1 0.5 - - 5 1.4
39 2 1.9 3 9.3 8 4.4 - - 13 3.6
45 2 1.9 2 6.2 4 2.2 3 7.5 11 3.0
51 9 8.7 1 3.1 17 9.4 3 7.5 30 8.4
52 7 6.7 - - 9 5.0 1 2.5 17 4.7
53 13 12.6 4 12.5 21 11.6 3 7.5 41 11.5
56 5 4.8 - - 11 6.1 1 2.5 17 4.7
58 4 3.8 3 9.3 8 4.4 - - 15 4.2
59 6 5.8 1 3.1 13 7.2 - - 20 5.6
66 5 4.8 - - 22 12.2 6 15.0 33 9.2
68 1 0.9 - - 5 2.7 1 2.5 7 1.9
73 4 3.8 1 3.1 8 4.4 1 2.5 14 3.9
82 1 0.9 - - 1 0.5 - - 2 0.5 
LR-HPVc
6 10 9.7 - - 8 4.4 1 2.5 19 5.3
11 4 3.8 - - 3 1.6 - - 7 1.9
40 - - - - - - - - - -
42 9 8.7 - - 17 9.4 3 7.5 29 8.1
54 3 2.9 - - 6 3.3 - - 9 2.5
55 4 3.8 - - 5 2.7 - - 9 2.5
61 10 9.7 3 9.3 23 12.7 2 5.0 38 10.7
62 11 10.6 3 9.3 16 8.8 - - 30 8.4
64 - - - - - - - - - -
67 1 0.9 1 3.1 4 2.2 - - 6 1.6
69 - - - - - - - - - -
70 3 2.9 2 6.2 6 3.3 1 2.5 12 3.3
71 1 0.9 - - - - - - 1 0.2
72 1 0.9 - - 2 1.1 1 2.5 4 1.1
81 4 3.8 - - 8 4.4 - - 12 3.3
83 1 0.9 - - 2 1.1 1 2.5 4 1.1
84 5 4.8 3 9.3 12 6.6 1 2.5 21 5.9
cp6108 9 8.7 4 12.5 14 7.7 1 2.5 28 7.8
a including 9 women with diagnosis of carcinoma
b high-risk/probable high-risk hpv types
c low-risk hpv types
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with a normal Pap test and with a significant preva-
lence also in ASCUS (12.5%), in LSIL (11.6%) and 
HSIL/carcinoma (7.5%). In women with ASCUS the 
most frequent HR-PHR genotypes found were type 16 
and type 31 (both 21.8%). In women with LSIL, the 
most frequent HR-PHR genotype, following type 16, 
was type 66 (12.2%). In HSIL/carcinoma women, oth-
er common HR-PHR genotypes, beside type 16, were 
types 18 and 66 (both 15.0%) followed by types 45, 51 
and 53 with 7.5%. Types 16 or 18 were detected in the 
33.2% of LSIL and in the 60.0% of HSIL/carcinoma. 
In particular, among women with carcinoma, 7 out of 9 
patients showed type 16, one type 18 and the remaining 
one type 66.
Among LR genotypes, type 61 was found in 10,7% 
(38/355) of HPV positive women, type 62 in 8.4% 
(30/355), type 42 in 8.2% (29/355) and type CP6108 in 
7.9% (28/355).
In women with a normal Pap test, the most frequent 
LR was type 62 (10.6%), in women with ASCUS type 
CP6108 (12.5%), in women with LSIL type 61 (12.7%) 
and in women with HSIL/carcinoma type 42 (7.5%). 
Discussion and conclusions
This study investigated the frequency and the distribution 
of HPV genotypes in a sample of women with known 
cytological results in the Puglia region (South Italy) dur-
ing the years 2005-2008. The overall prevalence of HPV 
infection (30.4%) was comparable to that of 31% found 
in a similar study conducted in Sardinia (Italy) [15]. 
A previous study conducted in Puglia [16] reported a 
prevalence of HPV infection in asymptomatic women 
of 23.1%, though the latter study did not describe the 
characteristics of the women nor their cytological results 
and used HPV-DNA detection and genotyping methods 
(multiplex PCR with four primer cocktails and detection 
by electrophoresis on 2% agarose gel) completely differ-
ent from the one we used. 
HPV occurrence in women with ASCUS, LSIL and 
HSIL/carcinoma was in line with the figures reported in 
other Italian studies [15, 17]. 
Despite the rate of HR-PHR HPV increases with the 
grade of the cytological result, the prevalence rates 
found for these diagnoses were lower than those recently 
reported in Southern Italy [18], although the percentages 
in the latter study refer to women with a known histo-
logical diagnosis. The low frequency of HPV infection 
we found in women with a cytological diagnosis of LSIL 
(47%), despite the use of validated broad spectrum PCR 
primer sets (PGMY09/11), is concerned. HPV-DNA 
prevalence values ranging from 55% to 92% have been 
reported in women with LSIL [19-22]. As previously re-
marked, a possible explanation could be the clearance of 
the virus before the resolution of the lesion, the presence 
of focal lesions not present in the samples tested [23] or, 
alternatively, false negative results. 
Another relevant finding is the absence of HPV-DNA 
in 6 cases of HSIL/carcinoma and the presence of LR in 
five case of HSIL/carcinoma. Because nearly all HSIL/
carcinoma women should be positive for HPV, the pos-
sibility of inadequacy of samples or variability in the 
cytological assessment may be invoked [22]. It should 
be also taken into account the possibility that events 
such as deletions in HPV L1 gene, which is the target 
of Polymerase chain reaction (PCR)-based test, could 
affect the detection [4]. The presence of LR in HSIL/
carcinoma has been previously reported [18], although 
further studied to clarify the possible role of HPV type 
considered at “low risk” in cervical lesions are needed. 
The prevalence of HPV infection in women with nor-
mal Pap smears (16.0%) was substantially in agreement 
with previous findings in Italian women with a normal 
cervix [15, 24]. 
An elevated proportion of HPV-positive women in our 
study are infected by HR-PHR genotypes. This empha-
sizes the need of an appropriate follow-up in women 
infected by HR-PHR because of the greater probabil-
ity that the presence of high-risk genotypes can lead to 
persistent infection and ultimately to cancer of the cer-
vix [5, 25].
A high rate of multiple HPV infections was found in the 
women studied (about 41% of the HPV positive wom-
en). Also other Italian studies showed high prevalence 
rates, varying from 30.9% to 49.7% [15, 18, 26], but the 
role of multiple infections in cervical lesions is not clear. 
However, these data should be considered for a correct 
evaluation of the impact of the vaccine in our region.
As expected, the most common genotype found was HPV 
type 16. The second most frequent genotype, among HR-
PHR HPV genotypes, was 53. A significant prevalence 
has also been found in women in the USA [27], where 
it is the most widespread (2.9% of women) and in Sicily 
(3.6% of all women) [18]. Also in Spain HPV type 53 
seems to be widespread [21]. 
The distribution of the genotypes according to cytologi-
cal diagnosis shows that HPV-16 is the most common 
in every group. For the HSIL/carcinoma group the sec-
ond most common genotypes were HPV-18 and HPV-
66. The genotypes 16, 18 and 66 together, seem to be 
responsible of 75% of cases of HSIL/carcinoma in the 
HPV-positive women of the present study. In addition, 
genotypes 66 and 53 had a significant prevalence also in 
women with LSIL. Further studies could better clarify 
the role of these genotypes in our area considering that 
such a peculiarity has not emerged in other reports in 
Italy [17, 24, 26, 28] and that vaccines against HPV to-
day in use do not cover these viral types. 
In Puglia data on incidence and mortality for cervical 
cancer are scarce. Screening by Pap test is still on vol-
untary basis although recently an organized cervical 
cancer-screening programme has been set up. Also HPV 
testing is not integrated in the screening programme for 
cervical cancer in Puglia and it is recommended only 
in ASCUS triage. Nevertheless, many studies have fo-
cused on the importance of HPV testing for cervical can-
cer screening [29-31]. The high prevalence of HR-PHR 
genotypes in our study underlines the need for introduc-
ing on larger scale HPV testing and also genotyping for 
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adequate follow up and correct clinical management of 
HPV infections. In addition, in epidemiologic surveys, 
type-specific HPV detection could contribute to the 
evaluation of HPV vaccine effectiveness.
Data on the frequency of HPV infection and on the gen-
otype distribution in Puglia (South Italy) may contribute 
to assess the impact of HPV vaccination and may pro-
vide further information for future decision-making. 
Based on our results, potentially, HPV vaccination 
with the bivalent [16, 18] vaccine in use in Puglia re-
gion could prevent about 34% of all infections, 33% of 
LSIL and 60% of HSIL/carcinoma. It should be consid-
ered that the bivalent vaccine has showed a potential 
of cross-protection effect against types 31 and 45 [32]. 
Therefore, hypothetical protection provided by vaccina-
tion with the bivalent vaccine in our region would reach 
46% of all infections, 45% of LSIL and about 67% of 
HSIL/carcinoma. 
The recent introduction of universal HPV vaccination 
among adolescents will probably modify the epidemio-
logical scenario of HPV infections in the coming years. 
Further studies should be aimed to evaluate the impact 
of vaccination in a younger cohort of women and knowl-
edge of HPV type distribution would provide the base 
for post-vaccination surveillance of circulating viral 
types and their clinical correlates.
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